Cell Death and Disease (Dec 2022)

RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling

  • Zhiguo Niu,
  • Jianing Fan,
  • Fengzhe Chen,
  • Huijie Yang,
  • Xin Li,
  • Ting Zhuang,
  • Chunlei Guo,
  • Qi Cao,
  • Jian Zhu,
  • Hui Wang,
  • Qingsong Huang

DOI
https://doi.org/10.1038/s41419-022-05473-6
Journal volume & issue
Vol. 13, no. 12
pp. 1 – 11

Abstract

Read online

Abstract Breast cancer is the most common malignancy in women on a global scale. It can generally be divided into four main categories, of which estrogen receptor ER-positive breast cancer accounts for most breast cancer cases. RBCK1 protein is an E3 ubiquitin ligase containing the UBL, NZF, and RBR domains. It is well known to exhibit abnormal expression in breast tumors, making it a valuable diagnostic marker and drug target. Additionally, studies have confirmed that in breast cancer, about 25 to 40% of tumors appear as visible hypoxic regions, while in hypoxia, tumor cells can activate the hypoxia-inducing factor HIF1 pathway and widely activate the expression of downstream genes. Previous studies have confirmed that in the hypoxic environment of tumors, HIF1α promotes the remodeling of extracellular matrix, induces the recruitment of tumor-associated macrophages (TAM) and immunosuppression of allogeneic tumors, thereby influencing tumor recurrence and metastasis. This research aims to identify RBCK1 as an important regulator of HIF1α signaling pathway. Targeted therapy with RBCK1 could be a promising treatment strategy for ER-positive breast cancer.